Skip to main content

Genomic Health Taps Medical Solutions to Distribute Oncotype DX in UK

NEW YORK (GenomeWeb News) — Genomic Health said today it has hired Medical Solutions to exclusively distribute its Oncotype DX breast cancer assay in the UK.
 
Chu Chang, vice president of business development at Genomic Health, said the agreement with the UK diagnostics and healthcare company is part of Genomic Health's strategy to broaden access to its test to patients outside of the US.
 
The Oncotype test predicts the likelihood of breast cancer recurrence in women with newly diagnosed, early stage invasive breast cancer. It also predicts the chance that chemotherapy will benefit “a large portion” of patients with early-stage breast cancer, the company said.
 
Genomic Health said it has service and supply agreements for the Oncotype in Israel and Japan. In the US the test is performed by CLIA-certified labs.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.